Sanofi EBITDA 2012-2026 | SNY
Sanofi annual and quarterly EBITDA history from 2012 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Sanofi EBITDA for the quarter ending June 30, 2026 was $2.500B, a 28.78% increase year-over-year.
- Sanofi EBITDA for the twelve months ending June 30, 2026 was $10.388B, a 7.74% increase year-over-year.
- Sanofi 2025 annual EBITDA was $16.255B, a 34.34% increase from 2024.
- Sanofi 2024 annual EBITDA was $12.1B, a 18.13% decline from 2023.
- Sanofi 2023 annual EBITDA was $14.78B, a 3.18% increase from 2022.
|
Sanofi Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $16,255 |
| 2024 | $12,100 |
| 2023 | $14,780 |
| 2022 | $14,324 |
| 2021 | $13,810 |
| 2020 | $20,597 |
| 2019 | $15,616 |
| 2018 | $11,286 |
| 2017 | $11,236 |
| 2016 | $11,245 |
| 2015 | $11,786 |
| 2014 | $13,555 |
| 2013 | $15,605 |
| 2012 | $14,858 |
| 2011 | $18,179 |
|
Sanofi Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $2,500 |
| 2026-03-31 | $2,441 |
| 2025-12-31 | $1,125 |
| 2025-09-30 | $4,321 |
| 2025-06-30 | $1,941 |
| 2025-03-31 | $2,443 |
| 2024-12-31 | $1,054 |
| 2024-09-30 | $4,204 |
| 2024-06-30 | $1,429 |
| 2024-03-31 | $1,533 |
| 2023-12-31 | $1,376 |
| 2023-09-30 | $3,502 |
| 2023-06-30 | $2,039 |
| 2023-03-31 | $2,676 |
| 2022-12-31 | $2,087 |
| 2022-09-30 | $4,309 |
| 2022-06-30 | $1,634 |
| 2022-03-31 | $2,691 |
| 2021-09-30 | $3,580 |
| 2021-03-31 | $2,527 |
| 2020-09-30 | $2,927 |
| 2020-03-31 | $2,338 |
| 2019-09-30 | $2,516 |
| 2019-03-31 | $1,538 |
| 2018-03-31 | $1,549 |
| 2017-12-31 | $1,188 |
| 2017-09-30 | $2,434 |
| 2017-06-30 | $1,596 |
| 2017-03-31 | $1,851 |
| 2016-12-31 | $1,842 |
| 2016-09-30 | $2,722 |
| 2016-06-30 | $1,724 |
| 2016-03-31 | $1,305 |
| 2015-09-30 | $2,308 |
| 2015-06-30 | $2,131 |
| 2014-06-30 | $1,977 |
| 2013-06-30 | $1,545 |
| 2012-06-30 | $5,370 |
| 2012-03-31 | $2,582 |
| 2011-12-31 | $2,047 |
| 2011-09-30 | $2,184 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $105.050B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |